Healthcare Industry News: endometriosis
News Release - January 25, 2011
Respected Gynecologist, Lipidologist Joins Atherotech Diagnostics Lab Medical Advisory BoardBIRMINGHAM, Ala.--(Healthcare Sales & Marketing Network)-- Atherotech Diagnostics Lab recently enlisted the expertise of two highly regarded physicians for its Medical Advisory Board.
Robert A. Wild, M.D., Ph.D., M.P.H., practices obstetrics and gynecology in Oklahoma City and teaches at the University of Oklahoma Health Sciences Center. Lipidologist John R. Nelson, M.D., M.D., F.A.C.C., F.N.L.A., F.A.S.N.C., is director of the California Cardiovascular Institute and volunteers as an assistant clinical professor at UCSF School of Medicine in Fresno, Calif.
As Medical Advisory Board members, Drs. Wild and Nelson will counsel Atherotech, maker of the patented VAP® Cholesterol Test, in the expansion of its disease management program. To review individual, detailed biographies, please visit http://www.atherotech.com/mad.
“The addition of Dr. Wild and Dr. Nelson gives Atherotech the ability to leverage their expertise when developing solutions to help physicians further mitigate cardiovascular disease risk in clinical patient care,” Atherotech Chief Medical Officer Michael E. Cobble said.
Dr. Wild is an experienced clinician and investigator with a focus on primary prevention strategies combining gynecology and preventive cardiology in women’s health. He has devoted more than 30 years to patient care, research and higher education by teaching medical students, residents, masters and Ph.D. students. His research interests include primary prevention strategies for women with a focus on lipids and the vascular system, reproductive endocrinology (Polycystic Ovarian Syndrome (PCOS) and endometriosis), sex steroids, lipoprotein lipids and cardiovascular diseases.
Dr. Nelson was a founding member of the Pacific Lipid Association and serves on its Board of Directors as president-elect. He is board certified in internal medicine–cardiovascular disease, nuclear cardiology, echocardiography, cardiovascular Computed Tomography, and is board certified in lipidology by the American Board of Clinical Lipidology. He is a Fellow of the American College of Cardiology, National Lipid Association and the American Society of Nuclear Cardiology. In 2008, Dr. Nelson was appointed as a volunteer assistant clinical professor at the UCSF School of Medicine–Fresno Medical Education Program. His role is to develop the lipid training program for Cardiology Fellows.
In 1999, a group of private investors acquired the assets of Birmingham-based Atherotech and the rights to a different kind of cholesterol test, called the Vertical Auto Profile (VAP), developed in the early 1990s by Dr. Jere Segrest of the University of Alabama at Birmingham’s Atherosclerosis Research Unit. Atherotech patented the advanced lipid profile and to date has performed more than 7.2 million VAP Tests. In 2009, Atherotech Diagnostics Lab expanded its testing panels to include more than a dozen cardiovascular and metabolic tests.
Atherotech’s VAP Test
The VAP Test is the only expanded lipid test that routinely reports directly measured LDL-C, which is included in the 22 reported cholesterol components — all at no additional cost. These components include Lp(a), apoB, apoA1, and the apoB/apoA1 ratio, making the VAP Test the only lipid profile that routinely reports all three lipid parameters — LDL, non-HDL and apoB — considered necessary by the American Diabetes Association and American College of Cardiology. The comprehensive lipid profile also identifies markers of metabolic syndrome, often associated with early diabetes.
For information on Atherotech, visit www.atherotech.com or call 877.901.8510. Atherotech Diagnostics Lab is on Twitter at www.Twitter.com/Atherotech and also on Facebook at www.Facebook.com/Atherotech.
About Atherotech Diagnostics Lab
Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company’s patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.atherotech.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.